Centrus Announces Multiple New Sales Contracts Valued at $165 Million

BETHESDA, Md.-- Centrus Energy Corp. (NYSE MKT: LEU) announced today that it has signed several new sales contracts in the last nine months to supply its utility customers with enriched uranium fuel. In aggregate, the contracts have a value of approximately $165 million with deliveries through 2022. They will help Centrus’ utility customers provide clean, affordable and reliable electricity around the world.

“We value our longstanding relationships with our customers and aim to remain a long-term supplier for their nuclear fleets,” said Centrus President and Chief Executive Officer Daniel B. Poneman. “For the past year, we have embraced a customer-first strategy, offering security, diversity and competitive pricing to the global nuclear fuel market.”

Sherritt Announces 2015 Production Results

TORONTO, ON--(Marketwired - January 18, 2016) - NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Sherritt International Corporation ("Sherritt") (TSX:S.TO) announced today its metals, Cuban oil production, and power production results for 2015 as follows:

CEMATRIX Corporation Secures Another $1.9 Million in Contracts

CALGARY, ALBERTA--(Dec 2, 2015) - CEMATRIX Corporation (TSX VENTURE:CVX) (the "Corporation" or the "Company" or "CEMATRIX") is pleased to announce that its wholly owned subsidiary, CEMATRIX (Canada) Inc. has secured another $1.9 million in contracts, in aggregate, for construction projects in Canada. Total contracted work is now a record $18.1 million, of which a record $15 million is slated for completion in 2015.

"The majority of these new contracts relate to infrastructure work in Eastern Canada, which is further confirmation of the continued growth of this market," stated Mr. Kendrick, President and CEO of CEMATRIX.

Graphene 3D Lab Announces R&D-Royalty Agreement with a Fortune 500 Manufacturer

NEW YORK, Dec. 1, 2015 - Graphene 3D Lab Inc. (TSXV: GGG) (OTCQB: GPHBF) ("Graphene 3D") and Graphene Laboratories Inc. are pleased to announce they have signed a research, development and royalty agreement ("Agreement") with a Fortune 500 listed manufacturer. Initially, the Agreement encompasses the development of multi-phased deliverables over the course of the next 12 months. For competitive reasons and pursuant to confidentially clauses contained with the Agreement, neither specific research objectives nor the identity of the Agreement partner can be publicly disclosed. Upon successful completion of the research phase, and subject to approval by the U.S. Food & Drug Administration, the developed materials will become a part of a consumer retail product.